Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 3/20 | 0.51 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.51 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5933395 | 0.91 | PTGER1 (0.53) | KDM1AHDAC1HDAC6KMOERN1 | |
| SCHEMBL120358 | 0.82 | AKR1C3 (0.63) | HDAC6KMOERN1MAP2K4AKR1C3 | |
| SCHEMBL16428977 | 0.81 | ESR2 (0.53) | KDM1AHDAC1HDAC6PFKFB3MEN1 | |
| SCHEMBL4350191 | 0.81 | CNR2 (0.52) | KMOERN1AKR1C3AKR1C2CA1 | |
| SCHEMBL2406313 | 0.81 | RXRA (0.58) | KMOERN1CA1CA2MEN1 | |
| SCHEMBL442496 | 0.80 | KMO (0.63) | KDM1AHDAC1HDAC6KMOERN1 | |
| SCHEMBL594843 | 0.79 | AKR1C3 (0.62) | KMOMAP2K4AKR1C3AKR1C2LMNA | |
| SCHEMBL121809 | 0.79 | KMO (0.68) | KMOERN1MAP2K4RXRARXRB | |
| SCHEMBL4334719 | 0.79 | LMNA (0.54) | ERN1MAP2K4CA1CA2LMNA | |
| SCHEMBL30146622 | 0.79 | BACE1 (0.62) | KDM1AHDAC1HDAC6PFKFB3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9586963-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2017-03-07 | — | — | US | disclosed |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2015-02-05 | — | — | US | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KDM1A 1515/4885HDAC1 4849/4885HDAC6 4487/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KDM1A 1515/4885HDAC1 4849/4885HDAC6 4487/4885 |
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | NR1D1, NR1D2, PER2 | KDM1A 2221/4885HDAC1 968/4885HDAC6 3242/4885 |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | KDM1A 2221/4885HDAC1 968/4885HDAC6 3242/4885 |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | KDM1A 2221/4885HDAC1 968/4885HDAC6 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.